Spyre Therapeutics Inc. - Asset Resilience Ratio
Spyre Therapeutics Inc. (SYRE) has an Asset Resilience Ratio of 83.49% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Spyre Therapeutics Inc. for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Spyre Therapeutics Inc.'s Asset Resilience Ratio has changed over time. See shareholders equity of Spyre Therapeutics Inc. for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Spyre Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Spyre Therapeutics Inc. (SYRE) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $421.30 Million | 83.49% |
| Total Liquid Assets | $421.30 Million | 83.49% |
Asset Resilience Insights
- Very High Liquidity: Spyre Therapeutics Inc. maintains exceptional liquid asset reserves at 83.49% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Spyre Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Spyre Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Spyre Therapeutics Inc. (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Spyre Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 84.42% | $513.66 Million | $608.48 Million | +40.43pp |
| 2023-12-31 | 43.99% | $150.38 Million | $341.86 Million | +14.69pp |
| 2022-12-31 | 29.30% | $20.85 Million | $71.14 Million | -41.64pp |
| 2021-12-31 | 70.94% | $77.99 Million | $109.93 Million | +36.18pp |
| 2020-12-31 | 34.76% | $56.18 Million | $161.62 Million | -28.59pp |
| 2019-12-31 | 63.35% | $52.70 Million | $83.18 Million | -3.61pp |
| 2018-12-31 | 66.96% | $52.05 Million | $77.74 Million | +0.12pp |
| 2017-12-31 | 66.84% | $37.48 Million | $56.08 Million | +43.35pp |
| 2016-12-31 | 23.49% | $15.75 Million | $67.06 Million | +13.74pp |
| 2015-12-31 | 9.75% | $3.77 Million | $38.65 Million | -- |
About Spyre Therapeutics Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a huma… Read more